Tamoxifen evolution.
作者信息
Howell A, Howell S J
机构信息
Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Prevent Breast Cancer Centre, Wythenshawe Hospital Manchester Universities Foundation Trust, Wythenshawe, Manchester, UK.
出版信息
Br J Cancer. 2023 Feb;128(3):421-425. doi: 10.1038/s41416-023-02158-5. Epub 2023 Feb 10.
Abstract
摘要
相似文献
1
Tamoxifen evolution.他莫昔芬的演变
Br J Cancer. 2023 Feb;128(3):421-425. doi: 10.1038/s41416-023-02158-5. Epub 2023 Feb 10.
2
The limits of tamoxifen.他莫昔芬的局限性。
Ir J Med Sci. 2002 Jan-Mar;171(1):8-9. doi: 10.1007/BF03168929.
3
Breast cancer patients can stop tamoxifen after 5 years.乳腺癌患者在5年后可以停用他莫昔芬。
West J Med. 2001 Jul;175(1):13. doi: 10.1136/ewjm.175.1.13.
4
Tamoxifen reduces breast cancer by a third in high risk women.他莫昔芬可使高危女性患乳腺癌的风险降低三分之一。
BMJ. 2002 Sep 21;325(7365):613. doi: 10.1136/bmj.325.7365.613/a.
5
Tamoxifen for the treatment and prevention of breast cancer: an update.他莫昔芬用于乳腺癌的治疗与预防：最新进展
Plast Surg Nurs. 2000 Winter;20(4):234-6. doi: 10.1097/00006527-200020040-00010.
6
Tamoxifen for early breast cancer.他莫昔芬用于早期乳腺癌。
Nurs Times. 2001;97(25):41.
7
Making use of modeling and simulations: Towards individualized tamoxifen therapy in breast cancer
.利用建模与模拟：迈向乳腺癌的他莫昔芬个体化治疗
Int J Clin Pharmacol Ther. 2017 Aug;55(8):690-691. doi: 10.5414/CPXCES15EA05.
8
[Adjuvant tamoxifen treatment in breast cancer: is 5-year treatment sufficient?].[乳腺癌的辅助他莫昔芬治疗：5年治疗足够吗？]
Ugeskr Laeger. 1997 Jun 16;159(25):3968-9.
9
CYP2D6 genotype and adjuvant tamoxifen.细胞色素P450 2D6基因分型与他莫昔芬辅助治疗
Clin Pharmacol Ther. 2014 Aug;96(2):138-40. doi: 10.1038/clpt.2014.96.
10
Adjuvant treatment with tamoxifen. Care is necessary.他莫昔芬辅助治疗。需谨慎。
BMJ. 1996 Aug 24;313(7055):493-4. doi: 10.1136/bmj.313.7055.493c.
引用本文的文献
1
Therapeutic resistance and combination therapy for cancer: recent developments and future directions.癌症的治疗耐药性与联合治疗：最新进展与未来方向
Sci Rep. 2025 Jul 24;15(1):26881. doi: 10.1038/s41598-025-12725-w.
2
Bile acids target an exposed cavity in the glucocorticoid receptor modulating receptor self-assembly, chromatin binding and transcriptional activity.胆汁酸作用于糖皮质激素受体上的一个暴露腔，调节受体的自组装、染色质结合和转录活性。
bioRxiv. 2025 May 16:2025.05.13.653693. doi: 10.1101/2025.05.13.653693.
3
Bibliometric Analysis of The Global Research Trends on The Application of Tamoxifen in The Treatment of Breast Cancer Over The Past 50 Years.过去50年他莫昔芬在乳腺癌治疗中应用的全球研究趋势的文献计量分析
Malays J Med Sci. 2025 Feb;32(1):35-55. doi: 10.21315/mjms-06-2024-452. Epub 2025 Feb 28.
4
Influence of CYP2D6 polymorphisms on tamoxifen side effects in patients with breast cancer.CYP2D6基因多态性对乳腺癌患者他莫昔芬副作用的影响。
Clin Transl Oncol. 2025 Apr 11. doi: 10.1007/s12094-025-03908-y.
5
Cardamom extract alleviates tamoxifen-induced liver damage by suppressing inflammation and pyroptosis pathway.小豆蔻提取物通过抑制炎症和焦亡途径减轻他莫昔芬诱导的肝损伤。
Sci Rep. 2025 Feb 8;15(1):4744. doi: 10.1038/s41598-025-89091-0.
6
Concurrent water T and fat fraction mapping of the breast using the radial gradient and spin echo (RADGRASE) pulse sequence.使用径向梯度和自旋回波（RADGRASE）脉冲序列对乳腺进行水T和脂肪分数的同步映射。
Magn Reson Imaging. 2025 May;118:110355. doi: 10.1016/j.mri.2025.110355. Epub 2025 Feb 5.
7
Interaction between Estrogen Receptors and p53: A Broader Role for Tamoxifen?雌激素受体与p53之间的相互作用：他莫昔芬的作用更广泛？
Endocrinology. 2025 Feb 5;166(3). doi: 10.1210/endocr/bqaf020.
8
Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review.乳腺癌信号级联的分子见解：综述
Cancers (Basel). 2025 Jan 13;17(2):234. doi: 10.3390/cancers17020234.
9
Low-dose tamoxifen treatment reduces collagen organisation indicative of tissue stiffness in the normal breast: results from the KARISMA randomised controlled trial.低剂量他莫昔芬治疗可减少正常乳房组织中的胶原组织，提示组织硬度降低：来自 KARISMA 随机对照试验的结果。
Breast Cancer Res. 2024 Nov 26;26(1):163. doi: 10.1186/s13058-024-01919-1.
10
-Ferrocene Derivatives as Potential Therapeutics.二茂铁衍生物作为潜在的治疗药物。
Molecules. 2024 Oct 16;29(20):4903. doi: 10.3390/molecules29204903.
本文引用的文献
1
Implementing Risk-Stratified Breast Screening in England: An Agenda Setting Meeting.在英国实施风险分层乳腺筛查：一次议程设定会议
Cancers (Basel). 2022 Sep 24;14(19):4636. doi: 10.3390/cancers14194636.
2
Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer.乳腺癌患者延长辅助激素治疗时间超过 5 年的决定因素和效果。
Cancer Res. 2022 Oct 4;82(19):3614-3621. doi: 10.1158/0008-5472.CAN-22-0900.
3
Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer-A Literature Review.评估激素受体阳性 HER2 阴性乳腺癌的辅助内分泌治疗——文献综述。
Curr Oncol. 2022 Jul 13;29(7):4956-4969. doi: 10.3390/curroncol29070394.
4
Topical Endoxifen for Mammographic Density Reduction-A Randomized Controlled Trial.局部应用依西美坦降低乳腺密度的随机对照研究。
Oncologist. 2022 Jul 5;27(7):e597-e600. doi: 10.1093/oncolo/oyac102.
5
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.Elacestrant（口服选择性雌激素受体降解剂）对比标准内分泌治疗用于雌激素受体阳性、人表皮生长因子受体 2 阴性的晚期乳腺癌：来自随机 III 期 EMERALD 试验的结果。
J Clin Oncol. 2022 Oct 1;40(28):3246-3256. doi: 10.1200/JCO.22.00338. Epub 2022 May 18.
6
Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the "My Personal Breast Screening" (MyPeBS) randomised clinical trial.研究方案比较了“我的个人乳腺癌筛查”（MyPeBS）随机临床试验中个体化乳腺癌筛查与标准筛查的伦理、心理和社会经济影响。
BMC Cancer. 2022 May 6;22(1):507. doi: 10.1186/s12885-022-09484-6.
7
Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer.他莫昔芬精准给药的依西美坦血药浓度监测：激素敏感型乳腺癌患者可行。
Clin Pharmacokinet. 2022 Apr;61(4):527-537. doi: 10.1007/s40262-021-01077-z. Epub 2021 Nov 17.
8
Time to Update Evidence-Based Guideline Recommendations About Concurrent Tamoxifen and Antidepressant Use? A Systematic Review.是时候更新关于他莫昔芬与抗抑郁药联合使用的循证指南建议了吗？一项系统评价。
Clin Breast Cancer. 2022 Apr;22(3):e362-e373. doi: 10.1016/j.clbc.2021.10.003. Epub 2021 Oct 9.
9
Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review.乳腺密度、内分泌治疗与乳腺癌风险：预后和预测生物标志物综述。
Cochrane Database Syst Rev. 2021 Oct 26;10(10):CD013091. doi: 10.1002/14651858.CD013091.pub2.
10
Searching for an ideal SERM: Mining tamoxifen structure-activity relationships.寻找理想的 SERM：挖掘他莫昔芬的构效关系。
Bioorg Med Chem Lett. 2021 Nov 15;52:128383. doi: 10.1016/j.bmcl.2021.128383. Epub 2021 Sep 27.
Zotero 插件